Verily

Verily. It is a life sciences and healthcare technology company operating as a subsidiary of Alphabet Inc., the parent company of Google. Founded in 2015 as a reorganization of Google X's life sciences division, the company focuses on developing tools and platforms to collect, organize, and activate health data. Its mission centers on enabling a transition from reactive healthcare to proactive and preventative health management through technological innovation.

History

The origins of Verily trace back to the life sciences division within Google X, the moonshot factory for ambitious technological projects led by Astro Teller. In December 2015, as part of a broader restructuring that created Alphabet Inc., the division was spun out as an independent subsidiary named Verily Life Sciences LLC, with molecular biologist Andrew Conrad as its founding CEO. This move reflected a strategic decision to separate exploratory research from Google's core internet products. Early initiatives inherited from its Google X days included the Google Baseline Study, a project aimed at defining what a "healthy" human looks like at a molecular level. The company quickly established its headquarters in South San Francisco, California, positioning itself within the heart of the San Francisco Bay Area's biotech corridor. Over the subsequent years, Verily expanded its scope through significant investments, internal project development, and a series of high-profile partnerships with established entities in the pharmaceutical industry and academic medicine.

Products and projects

Verily's portfolio encompasses a range of hardware, software, and clinical research platforms designed to address chronic diseases, surgery, mental health, and population health. Key hardware devices include the Study Watch, a research-grade wearable for continuous health monitoring, and the Verily Lens, a smart lens project initially investigated for non-invasive glucose monitoring in collaboration with Alcon. In software and data analytics, the Triton platform is designed to orchestrate complex clinical studies, while the Verily Value Suite aims to measure healthcare outcomes. Major long-term projects include the Project Baseline initiative, an effort to map human health by collecting comprehensive longitudinal data from participants, and the Debug Project, which sought to reduce mosquito-borne diseases like dengue fever through biological interventions. The company has also developed surgical robotics through its Verb Surgical joint venture and invested in Onduo, a virtual care platform for managing diabetes and other conditions.

Partnerships and collaborations

Strategic alliances form a core component of Verily's operational model, linking its technological capabilities with domain expertise from other sectors. A landmark partnership was formed with GlaxoSmithKline (GSK) to create Galvani Bioelectronics, a company focused on developing miniaturized implantable devices for bioelectronic medicine. In the field of surgical robotics, Verily collaborated with Johnson & Johnson to establish Verb Surgical, before later transitioning to a new entity named Ottava. The company has also engaged in numerous collaborations with leading academic and medical institutions, such as the Duke University School of Medicine, Stanford Medicine, and the American Heart Association, for large-scale health studies. Further partnerships with organizations like Walgreens, Singapore's Economic Development Board, and ResMed have aimed at deploying its technologies in retail health, national public health initiatives, and sleep apnea research, respectively.

Leadership and organization

Verily has been led by a series of executives with diverse backgrounds in technology and healthcare. Founding CEO Andrew Conrad, previously known for his work in genetic testing, led the company until 2018. He was succeeded by Stephen Gillett, a former Starbucks and Google executive, who initially served as Chief Operating Officer before becoming CEO. The company's leadership team includes veterans from firms like Intuitive Surgical, Genentech, and Microsoft. As a subsidiary of Alphabet Inc., Verily operates with a degree of autonomy but is ultimately overseen by Alphabet's board and executives like Ruth Porat. The company's structure includes multiple divisions or "podlets" focused on specific project areas, from research platforms to clinical interventions. It has raised significant external funding rounds from investors including Silver Lake, Temasek Holdings, and Ontario Teachers' Pension Plan, while remaining under Alphabet's majority ownership.

Impact and reception

Verily has generated significant attention for its ambitious, data-driven approach to healthcare challenges, though its efforts have yielded mixed results and faced scrutiny. Its large-scale studies, like Project Baseline, have been praised for their potential to revolutionize epidemiology and precision medicine by creating rich, longitudinal datasets. However, some projects, such as the glucose-sensing smart lens with Alcon, have been discontinued after failing to overcome technical hurdles. The company's foray into public health, like the Debug Project's mosquito release in Fresno, California, sparked public debate about the ethics and efficacy of such biotechnology interventions. Financially, Verily has consistently reported operating losses, which Alphabet Inc. has sustained as part of its long-term investment in life sciences. Within the industry, Verily is viewed as a major, well-capitalized player whose success hinges on translating technological innovation into clinically validated and commercially viable solutions that can integrate into existing healthcare systems like the National Institutes of Health frameworks or commercial insurance models.

Category:Alphabet Inc. subsidiaries Category:Biotechnology companies of the United States Category:Companies based in San Mateo County, California Category:Healthcare companies of the United States Category:Life sciences companies